Marker Therapeutics, Inc. (MRKR)
| Market Cap | 19.01M +31.1% |
| Revenue (ttm) | 3.55M -33.7% |
| Net Income | -10.90M |
| EPS | -0.63 |
| Shares Out | 16.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,185 |
| Open | 1.140 |
| Previous Close | 1.110 |
| Day's Range | 1.124 - 1.160 |
| 52-Week Range | 0.810 - 2.460 |
| Beta | 1.51 |
| Analysts | Strong Buy |
| Price Target | 7.87 (+590.35%) |
| Earnings Date | Aug 21, 2026 |
About MRKR
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreat... [Read more]
Financial Performance
In 2025, Marker Therapeutics's revenue was $3.55 million, a decrease of -46.19% compared to the previous year's $6.59 million. Losses were -$12.16 million, 13.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MRKR stock is "Strong Buy." The 12-month stock price target is $7.87, which is an increase of 590.35% from the latest price.
News
Marker Therapeutics Quarterly report: Q1 2026
Marker Therapeutics has published its Q1 2026 quarterly earnings report on May 18, 2026.
Marker Therapeutics Proxy statement: Proxy filing
Marker Therapeutics filed a proxy statement on March 20, 2026, providing details for shareholder voting and corporate governance matters.
Marker Therapeutics Proxy statement: Proxy filing
Marker Therapeutics filed a proxy statement on March 20, 2026, providing details for shareholder voting and corporate governance matters.
Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)
Reports FY25 revenue $3.5M, consensus $3.1M. “In 2025, we continued to advance MT-601, our lead Multi-Antigen Recognizing (MAR)-T cell therapy, and generated highly encouraging clinical data from our ...
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses
Marker Therapeutics Earnings release: Q4 2025
Marker Therapeutics released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
Marker Therapeutics Annual report: Q4 2025
Marker Therapeutics has published its Q4 2025 annual report on March 18, 2026.
Marker Therapeutics Proxy statement: Proxy Filing
Marker Therapeutics filed a proxy statement on March 10, 2026, providing details for shareholder voting and corporate governance matters.
Marker Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The MAR-T platform delivers a first-in-class, multi-antigen T-cell therapy with strong efficacy and an excellent safety profile in lymphoma, supported by durable responses and government funding. Expansion into solid tumors and an off-the-shelf AML program are underway.
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th...
Marker announces Baylor’s TACTOPS study featured on Good Morning America
Marker Therapeutics (MRKR) announced that Baylor College of Medicine’s TACTOPS clinical study in pancreatic cancer was featured on Good Morning America on Thursday, January 22, 2026. The segment spotl...
Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer
Marker Therapeutics (MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells, a technology developed at Baylor College of Medicine for ...
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study
Marker Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $10 price target The company’s pipeline of non-genetically engineered T cell-based immun...
Marker Therapeutics reports Q3 EPS (12c) vs (26c) last year
Reports Q3 revenue $1.23M vs $1.93M last year. “Marker entered the second half of 2025 with strong clinical momentum as we continue to advance our lead program, MT-601, in patients…
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma
Marker Therapeutics Earnings release: Q3 2025
Marker Therapeutics released its Q3 2025 earnings on November 14, 2025, summarizing the period's financial results.
Marker Therapeutics Quarterly report: Q3 2025
Marker Therapeutics has published its Q3 2025 quarterly earnings report on November 14, 2025.
Marker Therapeutics appoints Penkus Corzo to board of directors
Marker Therapeutics (MRKR) announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company’s Board of Directors, effective November 1, 2025. Most recently, Penkus Corzo served as Presiden...
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th...
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data
Marker Therapeutics announces first patient treated in off-the-shelf program
Marker Therapeutics (MRKR) announced that the first patient has been treated in the Company’s OTS program, with encouraging preliminary safety data. Marker is evaluating the safety and efficacy of esc...
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment
Marker Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Multi-TAA T-cell therapy shows promise in DLBCL and solid tumors, with strong safety and efficacy in heavily pretreated patients. Manufacturing is streamlined, and pivotal trials are planned for early next year, with off-the-shelf and solid tumor programs advancing.
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th...